Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 7/20 | 0.84 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | INSR | P06213 | 3/20 | 0.52 |
| ▸ | IGF1R | P08069 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12780131 | 0.91 | ZAP70 (1.00) | ZAP70PTK2ALKEGFRMAPK9 | |
| SCHEMBL12781668 | 0.91 | ZAP70 (0.91) | ZAP70PTK2ALKEGFRMAPK9 | |
| SCHEMBL12728763 | 0.87 | ZAP70 (0.64) | ZAP70PTK2ALKEGFRMAPK9 | |
| SCHEMBL12728533 | 0.83 | ZAP70 (0.59) | ZAP70PTK2ALKEGFRMAPK9 | |
| SCHEMBL12862487 | 0.82 | ZAP70 (0.77) | ZAP70PTK2ALKEGFRMAPK9 | |
| SCHEMBL12781151 | 0.81 | ZAP70 (0.75) | ZAP70PTK2ALKEGFRMAPK9 | |
| SCHEMBL12780077 | 0.81 | ZAP70 (0.74) | ZAP70PTK2ALKEGFRMAPK9 | |
| SCHEMBL12780497 | 0.81 | ZAP70 (0.74) | ZAP70PTK2ALKEGFRMAPK9 | |
| SCHEMBL12780203 | 0.80 | ZAP70 (0.72) | ZAP70PTK2ALKEGFRMAPK9 | |
| SCHEMBL12781068 | 0.79 | ZAP70 (0.71) | ZAP70PTK2ALKEGFRMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | ZAP70 341/4885PTK2 3952/4885ALK 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.